Patent · US Active

Treatment of cancer using a CD33 chimeric antigen receptor

US10851166B2 · kind B2 · utility

1Cited by

45References

22Claims

0Family size

Assignees

Novartis AG · CH
The Trustees of the University of Pennsylvania · US

Inventors

Hilmar Erhard Ebersbach · Basel, CH
Thomas Huber · Basel, CH
Julia Jascur · Basel, CH
Celeste Richardson · Cambridge, US
Reshma Singh · Cambridge, US
Huijuan Song · Shanghai, CN
Qilong Wu · Shanghai, CN
Jiquan Zhang · Shanghai, CN

Key dates

Filing date	Aug 29, 2017
Grant date	Dec 1, 2020
Priority date	—
Expiry date	Dec 24, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/70
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.